4.5 Article

Australia's national Q fever vaccination program

Journal

VACCINE
Volume 27, Issue 14, Pages 2037-2041

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.02.007

Keywords

Q fever; Australia; Immunisation

Funding

  1. Australian Government Department of Health and Ageing
  2. NSW Department of Health
  3. Children's Hospital at Westmead

Ask authors/readers for more resources

A nationally funded Q fever vaccination program was introduced in Australia in 2002. The evaluation of this unique program included measures of program uptake, safety, and notification and hospitalisation rates for Q fever pre- and post-program implementation. Program uptake ranged from close to 100% amongst abattoir workers to 43% in farmers. The most commonly reported adverse event was injection site reaction. Q fever notification rates declined by over 50% between 2002 and 2006, particularly in young adult males, consistent with the profile of the abattoir workforce. Hospitalisation data showed similar trends. Available evidence suggests a significant impact of Australia's Q fever vaccination program: such a program merits consideration in other countries with a comparable Q fever disease burden. (C) 2009 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Pertussis Disease and Antenatal Vaccine Effectiveness in Australian Children

Helen E. Quinn, Jeannette L. Comeau, Helen S. Marshall, Elizabeth J. Elliott, Nigel W. Crawford, Christopher C. Blyth, Jennifer A. Kynaston, Tom L. Snelling, Peter C. Richmond, Joshua R. Francis, Kristine K. Macartney, Peter B. McIntyre, Nicholas J. Wood

Summary: Maternal antenatal vaccination can reduce the incidence of pertussis in infants under 2 months of age. Age-appropriate vaccination and control of comorbidities are also important for preventing pertussis in children.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2022)

Article Immunology

Pertussis burden and acellular pertussis vaccine effectiveness in high risk children

Sarah Sheridan, Peter McIntyre, Bette Liu, Parveen Fathima, Thomas Snelling, Christopher Blyth, Nicholas de Klerk, Hannah Moore, Heather Gidding

Summary: The study found that improving the timeliness of current infant doses and increasing antenatal coverage can enhance protection against pertussis for most Aboriginal and non-Aboriginal children. Children at highest risk of severe pertussis may benefit from additional measures such as extra doses of pertussis-containing vaccines or vaccines with improved immunogenicity.

VACCINE (2022)

Letter Medicine, General & Internal

The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020-March 2021

Archana Koirala, Heather F. Gidding, Kaitlyn Vette, Kristine Macartney

MEDICAL JOURNAL OF AUSTRALIA (2022)

Article Immunology

Severity of Rotavirus-Vaccine-Associated Intussusception: Prospective Hospital-Based Surveillance, Australia, 2007-2018

Meru Sheel, Nicholas Wood, Kristine Macartney, Jim Buttery, Nicole Dinsmore, Helen Marshall, Elizabeth Elliott, Anne Kynaston, Peter Richmond, Dan Chateau, Peter McIntyre

Summary: Studies have found that cases of intussusception within 21 days of receiving rotavirus vaccine are more severe and occur at a younger age. However, after adjusting for age and sex, the severity of intussusception is not related to the vaccine.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2022)

Article Multidisciplinary Sciences

Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020

Dorothy A. B. Machalek, Kaitlyn M. Vette, Marnie Downes, John B. O. Carlin, Suellen B. Nicholson, Rena F. Hirani, David O. Irving, Iain B. Gosbell, Heather F. Gidding, Hannah M. Shilling, Eithandee Aung, Kristine Macartney, John M. Kaldor

Summary: This study estimated the seroprevalence of SARS-CoV-2 antibodies among blood donors in metropolitan Melbourne during the COVID-19 outbreak. The results suggest low community transmission and good case ascertainment during the second epidemic wave. The study highlights the usefulness of residual blood donor samples in assessing seroprevalence and population patterns of infection.

PLOS ONE (2022)

Article Immunology

Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection

Bette Liu, Heather Gidding, Sandrine Stepien, Michelle Cretikos, Kristine Macartney

Summary: In a mostly infection-naive but highly vaccinated population in Australia, receiving a third dose of COVID-19 vaccine significantly reduced hospitalizations and deaths from SARS-CoV-2 Omicron infections in individuals aged 40 years and above.

VACCINE (2022)

Article Immunology

When should a longer needle be used for intramuscular injection in obese patients? A combined analysis of New Zealand data

Marjan Doppen, Cilein Kearns, Mark Weatherall, Nethmi Kearns, Peter McIntyre, Thomas Hills, Richard Beasley

Summary: This study aimed to determine the thresholds for Body Mass Index (BMI) and arm circumference above which a longer needle is needed for intramuscular (IM) delivery of a vaccine in the deltoid muscle at the recommended site in New Zealand. The analysis of two studies involving 442 adults showed that higher arm circumference and BMI values were associated with the need for a longer needle. Based on the findings, men with an arm circumference of 35 cm and women with an arm circumference of 30 cm should use a longer needle to ensure successful intramuscular injection.

VACCINE (2023)

Article Immunology

Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines

Alexis Pillsbury, Anastasia Phillips, Lucy Deng, Helen Quinn, Kristine Macartney, Heather Gidding

Summary: This study aimed to determine the background rates of adverse events following COVID-19 vaccination using healthcare data from Australia's most populous state. The study found low background rates for selected neurological conditions, but high rates for generalised convulsions. Thromboembolic and cerebral venous sinus thrombosis event rates increased with age, and myocarditis was more common in males, particularly those aged 18-24.

VACCINE (2023)

Article Immunology

Pneumococcal Conjugate Vaccines Are Protective Against Respiratory Syncytial Virus Hospitalizations in Infants: A Population-Based Observational Study

Huong Le, Heather Gidding, Christopher C. Blyth, Peter Richmond, Hannah C. Moore

Summary: Through population-based linked data analysis, we have demonstrated the real-world protective effect of pneumococcal conjugate vaccines on respiratory syncytial virus hospitalizations in infants. These findings are particularly relevant for areas with a high burden of respiratory syncytial virus but no widespread pneumococcal conjugate vaccine program.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Immunology

Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection

Bette Liu, Sandrine Stepien, Jiahui Qian, Heather Gidding, Katrina Nicolopoulos, Janaki Amin, Allen Cheng, Kristine Macartney

Summary: This study compared the effectiveness of different COVID-19 vaccines. The results showed that the BNT162b2 mRNA vaccine had higher effectiveness in preventing primary infections compared to mRNA-1273, ChAdOx-1 nCov-19, and NVX-CoV2373. For booster doses, the BNT162b2 mRNA vaccine also showed good effectiveness.

VACCINE (2023)

Article Immunology

Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data

Huong Le, Nicholas de Klerk, Christopher C. Blyth, Heather Gidding, Parveen Fathima, Hannah C. Moore

Summary: This study assesses the causal impact of seasonal influenza vaccine on respiratory syncytial virus (RSV) hospitalizations in children using an instrumental variable strategy. The results show that influenza vaccine reduces the risk of RSV hospitalizations, especially in children under 2 years old.

VACCINE (2023)

Editorial Material Health Care Sciences & Services

Pertussis deaths in New Zealand without community transmission-an infant immunity gap?

Peter B. Mcintyre, Emma Best, Catherine A. Byrnes, Owen Sinclair, Adrian Trenholme, Cameron C. Grant

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2023)

Review Infectious Diseases

Australian vaccine preventable disease epidemiological review series: measles, 2012-2019

Noni E. Winkler, Aditi Dey, Helen E. Quinn, Davoud Pourmarzi, Stephen Lambert, Peter McIntyre, Frank Beard

Summary: This review examined measles data in Australia from 2012 to 2019. The findings show a low incidence of measles, with most cases being imported or linked to imported cases. The study emphasizes the importance of vaccination for prevention, particularly among unvaccinated individuals. Monitoring of waning immunity in older age groups is also highlighted as a concern.

COMMUNICABLE DISEASES INTELLIGENCE (2022)

Article Infectious Diseases

How accurately does the Australian Immunisation Register identify children overdue for vaccine doses? A national cross-sectional study

Lauren G. Dalton, Kelley N. Meder, Frank H. Beard, Aditi Dey, Brynley P. Hull, Kristine K. Macartney, Peter B. McIntyre

Summary: This study assessed the accuracy of data recorded in the Australian Immunisation Register and found a high error rate in classifying overdue vaccine records, with significantly more errors when records were transmitted by paper-based methods. Uniform use of practice management software is recommended for better accuracy in vaccine data recording.

COMMUNICABLE DISEASES INTELLIGENCE (2022)

Article Infectious Diseases

Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study

Alamgir Kabir, Anthony T. Newall, Deborah Randall, Hannah C. Moore, Sanjay Jayasinghe, Parveen Fathima, Bette Liu, Peter McIntyre, Heather F. Gidding

Summary: This population-based retrospective cohort study estimated that the 7-valent pneumococcal conjugate vaccine was highly effective against vaccine-type (91.1%) and all-cause (82.5%) invasive pneumococcal disease in children with medically at-risk conditions in Australia.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2022)

No Data Available